Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335777 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL8886861 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL13363641 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL144832 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL767076 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL12070284 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL7087412 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL7774670 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL8011422 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL766860 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-4159205-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-4159204-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023230541-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-4265300-A2 | COMBINATION | Novartis AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230295313-A1 | IL1RAP BINDING PROTEINS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-4242206-A1 | CRYSTALLINE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHENYL)METHYL]ETHYL}-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE | Novartis AG (CH) | 2023-09-13 | — | — | EP | disclosed |
| EP-4159204-A1 | NOVEL PHARMACEUTICAL COMPOSITION | Novartis AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005079192-A2 | NOVEL TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005034873-A2 | A METHOD FOR REDUCING ANTI-NEOPLASTIC AGENT INDUCED SIDE-EFFECTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1512413-A2 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1488809-A1 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1353693-A2 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | GLAXO GROUP LIMITED (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1289557-A2 | CANCER TREATMENT COMPOSITION CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002056912-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001093909-A2 | CANCER TREATMENT COMPOSITION CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295313-A1 | IL1RAP BINDING PROTEINS | IL1RN, IL1R1, IL1A | CTSK 1902/4885CTSS 1825/4885GABRB1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.